Answers are grounded in this paper and cite their sources.
Heart failure (HF) is a pathology of increasing prevalence in the world population, characterized by the progressive loss of functionality of the cardiac muscle and which is directly related to several comorbidities that are also very common, such as systemic arterial hypertension, ischemic myocardial disease, diabetes mellitus, obesity, amyloidosis, and among other pathologies.[1] In recent years, there has been a growing effort in the search for a better understanding of the pathophysiology that involves this condition and the consequent search for therapeutic options with an impact on morbidity and mortality related to the disease.[2] Phlorizin is a naturally occurring phenol glycoside first isolated from the root bark of the apple tree in 1835. Early studies in animals showed that oral ingestion of phlorizin causes renal glycosuria and weight loss without hyperglycemia. However, it was not until the 1930s that it was first tested in humans. The therapeutic potential of phlorizine is limited by poor oral bioavailability because of its tendency to be hydrolyzed in the gut to its aglycone and phloretin. Because the majority of filtered glucose is reabsorbed in the early proximal convoluted tubule and because nonselective sodium-glucose cotransporter (SGLT) inhibitors may also block glucose transporter 1, research has focused specifically on SGLT2 as a molecular target to increase urinary glucose excretion. Chemically, most SGLT2 inhibitors are glycosides derived from the prototype, phlorozin. SGLT2 inhibitors act on the proximal convoluted tubule of the nephron, inhibiting the reabsorption of sodium and glucose.[3] This therapeutic effect was initially shown to be beneficial for the treatment of type 2 diabetes mellitus (T2DM). However, based on the cardiovascular (CV) safety studies necessary for the approval of these drugs for clinical use, an intimate relationship between this pathophysiological mechanism and HF was revealed. Studies such as EMPA-REG OUTCOME,[4] CANVAS Program,[5] and DECLARE–TIMI 58[6] demonstrated an important impact of this therapeutic class in the reduction of HF-related events in patients with T2DM. Mechanisms potentially related to this benefit include stimulation of natriuresis, reduction of interstitial edema, improvement of cardiac energy metabolism through greater availability of ketone bodies, inhibition of sodium–hydrogen exchange in cardiomyocytes, reduction of preload and afterload of the left ventricular wall stress, in addition to improvement in renal function.[7] In recent years, there has been a marked increase in effective therapies for the treatment of HF.[8] The use of these therapies reduced three-point major adverse CV events[3] defined as nonfatal myocardial infarction, stroke, and CV death; hospitalization for HF (HHF); as well as renal outcomes.[9] Previously, studies in HF with reduced ejection fraction (HFrEF) have shown improvement in hard outcomes. However, clinical trials on HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) did not have the same success until the emergence of SGLT2 inhibitors. Dedicated HF trials have tried to evaluate the efficacy of SGLT2 inhibitors in patients with HF, regardless of ejection fraction, among them dapagliflozin, empagliflozin, and sotagliflozin. Dapagliflozin and Prevention of Adverse HF (DAPA-HF) trial[10] was the first published study with a specific design to evaluate the effectiveness of SGLT2 inhibitors in patients with HFrEF. The second study was the EMPEROR-Reduced[11] using empagliflozin in patients also with HFrEF, evaluating the composite outcomes of CV death or HHF. Both studies demonstrated the efficiency and safety of the medication. Subsequently, SGLT2 inhibitors were tested in HFpEF patients in the EMPEROR-Preserved[12] with empagliflozin on CV death or HHF in patients with HF with mildly reduced or preserved ejection fraction (HFmrEF/HfpEF and the DELIVER trial with dapagliflozin showing similar results for patients with HFmrEF/HFpEF.[13] Interestingly, sotagliflozin (the first dual SGLT1/SGLT2 inhibitor) demonstrated benefits in a population with T2DM and recent hospitalization due to HF decompensation in the SOLOIST-WHF[14] very similar to EMPEROR-Pooled analysis[15] of either CV death or HF hospitalization. A polled analysis of patients from the DAPA HF and DELIVER studies was performed and demonstrated that dapagliflozin, regardless of ejection fraction, can be used in HF, with consistent results across the entire spectrum of the disease.[16] A first prespecified analysis demonstrated that dapagliflozin reduced the risk of death from all causes (heart rate [HR] 0.90, 0.82–0.99 P = 0.03), death from CV causes (HR 0.86, 0.76–0.97 P = 0.01), and severe CV events (HR 0.90, 0.81–1.00 P = 0.045). Direct head‐to‐head comparisons among SGLT2 inhibitors treatments in established HF remain absent. Chen etal.[17] recently conducted a systematic review of dedicated HF trials with the Bayesian approach to network meta‐analysis to assess indirectly the composite outcomes and individual clinical endpoints among SGLT2 inhibitor treatments. There was no significant difference in the major efficacy outcomes among SGLT2 inhibitor treatments; however, sotagliflozin may be associated with the lowest risk of the composite of CV death or HHF, and dapagliflozin may be associated with the lowest risk of all‐cause and CV mortality. The consistency of these findings, especially the reduction in HF hospitalizations indicated that SGLT-2 inhibitors may have an independent role in the management of HF.[18] The U.S. Food and Drug Administration on May 26 approved sotagliflozin, the first dual SGLT1 and SGLT2 inhibitor for the treatment of HF, including HFrEF and HFpEF. Ongoing studies are seeking to assess the impacts of other conditions such as, for example, atrial fibrillation and in older patients.[19] Interesting to note that given its dual action on SGLT1 and SGLT2, sotagliflozin significantly reduced HbA1c levels in patients with estimated glomerular filtrations rates < 30 mL/min/1.73 m2 and those with less impairment. The SGLT1 is the primary transporter for the absorption of glucose and galactose in the gastrointestinal tract. Inhibition blunts and delays postprandial glucose (PPG) excursion. SGLT2 is expressed in the kidney, where it reabsorbs 90% of filtered glucose. Thus, a dual SGLT1 and SGLT2 inhibition (compared with selective SGLT2 inhibition) could result in lower PPG and robust A1c reduction even in patients with reduced kidney function.[19] It is also worth remembering that these medications have an important impact on the prevention of chronic kidney disease (CKD) or on its stabilization in patients already affected. These data also motivated the approval for CKD and show the intimate relationship between renal alterations and cardiac outcomes. Thus, nowadays, it is important to understand that the care of the patient with HF must be integrated with the care of blood glucose, kidney disease, and other relevant aspects of cardiometabolic management. The discussion that is imposed for the future is the possibility of primary prevention of HF, considering the related risk factors. These medications would have the potential to prevent the patient from developing this condition, generating cardiomyocyte preservation in the medium–long term, and resulting in an effect similar to that of statins in patients with a predisposition to clinical or subclinical atherosclerosis.[20]
No takes yet. Share an insight, caveat, or question.
Custódio et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: